News Category AllNon-regulatory ReleasesRegulatory Releases Year All2024202320222021202020192018 May 17, 2024 Oculis updates share capital for its existing at-the-market offering program May 8, 2024 Oculis Reports Q1 2024 Financial Results and Provides Company Updates May 8, 2024 Oculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic Neuritis May 6, 2024 Oculis to Present at Bank of America Global Healthcare Conference Apr 29, 2024 Oculis Publishes Invitation to the Annual General Meeting Apr 22, 2024 Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market Apr 22, 2024 Oculis Mourns the Loss of Chief Scientific Officer Professor Ramin Tadayoni Apr 11, 2024 Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market Apr 10, 2024 Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Development Apr 8, 2024 Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting